seed
Stage
2
Investors
About
Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an inhaled inhibitor targeting PDGFRα/β, CSF1R, and c-KIT, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Explore Gossamer Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.